SCHEMBL13102338

SCHEMBL13102338

Cc1ccc(C(=O)NCc2nccs2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.62
▸ NPC1 O15118 5/20 0.62
▸ RAB9A P51151 4/20 0.62
▸ KDM4E B2RXH2 2/20 0.52
▸ ROCK2 O75116 1/20 0.52
▸ ADORA2A P29274 1/20 0.51
▸ PSMD14 O00487 1/20 0.51
▸ STAMBP O95630 1/20 0.51
▸ COPS5 Q92905 1/20 0.51
▸ HTT P42858 2/20 0.49
▸ MMP2 P08253 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ STAT3 P40763 1/20 0.49
▸ MMP13 P45452 1/20 0.49
▸ MAPK14 Q16539 1/20 0.49
▸ SCN3A Q9NY46 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ KMT2A Q03164 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1568306 0.85 ROCK2 (0.57) SMN1; SMN2NPC1RAB9AKDM4EROCK2
SCHEMBL13118304 0.85 NPC1 (0.60) NPC1RAB9AKDM4EROCK2ADORA2A
SCHEMBL14724679 0.85 NR1H4 (0.53) SMN1; SMN2NPC1RAB9AKDM4EROCK2
SCHEMBL1393311 0.83 NPC1 (0.64) SMN1; SMN2NPC1RAB9AROCK2PSMD14
SCHEMBL18085951 0.83 ROCK2 (0.58) NPC1RAB9AROCK2ADORA2APSMD14
SCHEMBL31468372 0.82 EPHX2 (0.50) SMN1; SMN2NPC1RAB9AKDM4EROCK2
SCHEMBL21875133 0.80 GRM4 (0.47) SMN1; SMN2NPC1RAB9AKDM4EPSMD14
SCHEMBL2936249 0.77 KDM4E (0.46) SMN1; SMN2NPC1RAB9AKDM4EPSMD14
SCHEMBL3223685 0.77 RAB9A (1.00) SMN1; SMN2NPC1RAB9AKDM4EADORA2A
SCHEMBL31468438 0.76 PSMD14 (0.57) SMN1; SMN2NPC1RAB9AROCK2PSMD14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349839-B2 Inhibitors of HIV replication BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-08 — — US disclosed
US-20100261714-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261714-A1 INHIBITORS OF HIV REPLICATION RTF2, POLR1A, REV1 SMN1; SMN2 4527/4885NPC1 1005/4885RAB9A 1780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback